ANGLE plc Secures Funds to Boost Cancer Care

ANGLE plc (GB:AGL) has released an update.

ANGLE plc, a leading liquid biopsy company, has successfully completed a fundraising initiative, securing £8.775 million through the placement of shares and subscriptions at a 16.7% discount to its last closing price. The funds raised are set to bolster the company’s commercial momentum in personalized cancer care, capitalizing on their FDA-cleared Parsortix system. Additionally, an Open Offer aims to raise further capital by allowing shareholders the opportunity to subscribe for new shares at the same discounted price.

For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.